阅读说明：本技术 改进的多核苷酸序列检测方法 (Improved polynucleotide sequence detection method ) 是由 巴纳比·巴姆福思 卡梅伦·弗雷林 安娜·席尔瓦-韦瑟利 马格达莱纳·斯托拉雷克-雅努什凯维奇 于 2019-07-19 设计创作，主要内容包括：一种检测给定核酸分析物中的靶多核苷酸序列的方法,其特征在于以下步骤：a.将分析物退火至单链探针寡核苷酸A_0,以产生为至少部分双链并且其中A_0的3’末端与分析物靶序列形成双链复合物的第一中间产物；b.使用焦磷酸解酶从A_0的3’末端在3’-5’方向上焦磷酸解第一中间产物,以产生部分消化的链A_1和分析物；c.(i)将A_1退火至单链触发寡核苷酸B,并在5’-3’方向上针对B延伸A_1链；或者(ii)通过连接A_1的3’和5’末端使其环化；或者(iii)将A_1的3’末端连接到连接探针寡核苷酸C的5’末端；在每种情况下产生寡核苷酸A_2；d.用至少一种单链引物寡核苷酸引发A_2,并产生A_2或A_2的区域的多于一个拷贝；和e.检测来源于多于一个拷贝的信号,并从其推断分析物中存在或不存在多核苷酸靶序列。(A method of detecting a target polynucleotide sequence in a given nucleic acid analyte, characterized by the steps of: a. annealing of analyte to Single Strand Probe oligonucleotide A 0 To produce a double-stranded DNA sequence which is at least partially double-stranded and in which A 0 Forms a first intermediate product of a double-stranded complex with the analyte target sequence; b. using pyrophosphorolytic enzyme from A 0 Is pyrophosphorolysis of the first intermediate product in the 3 '-5' direction to produce partially digested strand A 1 And an analyte; c. (i) mixing A with 1 Annealing to a single stranded trigger oligonucleotide B and extending in the 5 '-3' direction against BStretch A 1 A chain; or (ii) by a linkage A 1 Cyclizing the 3 'and 5' termini thereof; or (iii) A 1 Is ligated to the 5' end of the ligation probe oligonucleotide C; in each case generating oligonucleotides A 2 (ii) a d. Priming A with at least one Single-Strand primer oligonucleotide 2 And produce A 2 Or A 2 More than one copy of the region of (a); detecting a signal derived from more than one copy and inferring therefrom the presence or absence of the polynucleotide target sequence in the analyte.)

1. A method of detecting a target polynucleotide sequence in a given nucleic acid analyte, characterized by the steps of:

a. annealing the analyte to a single-stranded probe oligonucleotide A₀To produce a double-stranded DNA sequence which is at least partially double-stranded and in which A₀Forms a first intermediate product of a double-stranded complex with the analyte target sequence;

b. using pyrophosphorolytic enzyme from A₀Is pyrophosphorolysis of the first intermediate product in the 3 '-5' direction to produce a partially digested strand A₁And the analyte;

c. (i) mixing A with₁Annealing to a single stranded trigger oligonucleotide B and extending said A in the 5 '-3' direction towards B₁A chain; or (ii) by a linkage A₁Cyclizing the 3 'and 5' termini thereof; or (iii) A₁Is ligated to the 5' end of the ligation probe oligonucleotide C; in each case generating oligonucleotides A₂；

d. Priming A with at least one Single-Strand primer oligonucleotide₂And produce A₂Or A₂More than one copy of the region of (a); and

e. detecting a signal derived from said more than one copy and inferring therefrom the presence or absence of said polynucleotide target sequence in said analyte.

2. The process according to claim 1, wherein c (ii) or c (iii) is used, characterized in that A₁Extending first in the 5 '-3' direction prior to attachment.

3. Method according to claim 1 or 2, wherein said connecting and optionally said extending is by addingA further splint oligonucleotide D, A₁Annealing to said splint oligonucleotide D prior to ligation, wherein D comprises a₁And an oligonucleotide region complementary to the 3' terminus of oligonucleotide C or to A₁A region complementary to the 5' end of (a).

4. The method of claim 3, wherein the oligonucleotide D is modified by 3 'modification or by the 3' terminus of the oligonucleotide and A₁The oligonucleotide D cannot be directed against A₁And (4) extending.

5. The method of claims 1 to 4, further characterized in that after step (C), the reaction mixture is treated with exonuclease to substantially eliminate any unligated nucleic acid material, and wherein if C (ii) is used, the oligonucleotide C further comprises a 3' or internal modification that protects it from digestion by 3' -5 ' exonuclease.

6. The method of claim 5, further characterized in that prior to step (d), the exonuclease is inactivated.

7. The method of claim 1 wherein c (i) is used, wherein B comprises (i) and A₁And (ii) at its 5' end a flanking oligonucleotide region complementary to A₀Or said target sequences are not substantially complementary, and characterized in that one of the primer oligonucleotides used in step (d) anneals to A₂The extension region of (3).

8. The method of any preceding claim, wherein the probe oligonucleotide A₀Having a 5' end resistant to exonucleolysis and characterised in that after steps (a) and (b) the reaction medium thus produced is treated with a 5' -3 ' exonuclease to substantially remove any nucleic acid molecules which are not resistant to such exonucleolysis.

9. A method according to claim 8, characterized in that the exonuclease used has an activity which is at least partly dependent on the presence of a 5' phosphate group and in that the digestion is carried out in the presence of a kinase and a phosphate donor.

10. The method according to any one of the preceding claims, wherein step (b) is carried out in the presence of a phosphatase.

11. The method of any of the preceding claims, further characterized by iterating steps (a) and (b) to produce a partially digested probe a from the analyte₁More than one copy.

12. The method according to any one of the preceding claims, characterized in that the pyrophosphorolysis reaction is stopped after step (b) by adding pyrophosphatase.

13. The method of any preceding claim, wherein step (e) comprises detecting signals derived from the more than one copy using one or more oligonucleotide binding dyes or molecular probes.

14. The method according to any of the preceding claims, characterized in that steps (d) and (e) are carried out simultaneously.

15. The method of claim 14, wherein the increase in signal over time resulting from the generation of amplicons in step (d) is used to infer the concentration of the target sequence in the analyte.

16. The method of any one of the preceding claims, wherein prior to step (a), the single-stranded analyte is derived from the biological sample by: (i) generating an amplicon of the analyte by subjecting a biological sample comprising the analyte and optionally background genomic DNA to an amplification cycle, and (ii) digesting the product of step (i) with an exonuclease having 5 '-3' exonuclease activity, wherein one of the primers used comprises an exonuclease blocking group.

17. The method of any one of claims 1 to 15, wherein prior to step (a), the single stranded analyte is derived from the biological sample by: (i) generating amplicons of the analyte by performing an amplification cycle on a biological sample comprising the analyte and optionally background genomic DNA, wherein one of the primers used is introduced in excess of the other primers.

18. The method of claim 16 or 17, wherein the amplification method used in step (i) uses a polymerase that exhibits 3 '-5' exonuclease activity, and wherein after step (i) the product is reacted with a protease to disrupt the polymerase, and wherein the protease is subsequently disrupted by heating the product of the reaction.

19. The method of claims 16 to 18, wherein step (i) is performed using deoxyuridine triphosphate instead of deoxythymidine triphosphate and in the presence of UTP-DNA diglycolase.

20. Method according to any of the preceding claims, characterized in that more than one probe A is used₀Each probe A₀Has selectivity for different target sequences, and each probe A₀Comprising a recognition region and further characterized in that the region amplified in step (d) comprises the recognition region.

21. The method of claim 20, further characterized by probe a from which the amplicon generated in step (d) is derived₀Derivatisation is performed and the target sequence present in the analyte is therefore deduced by detecting the recognition zone.

22. The method of claim 21, wherein the detection of the recognition region is performed using a molecular probe or by sequencing.

23. The method of claim 22, wherein (e) further comprises the steps of:

i. labelling A with one or more oligonucleotide fluorescent binding dyes or molecular probes₂Or A₂More than one copy of the region of (a);

measuring the fluorescence signal of the more than one copy;

exposing the more than one copy to a set of denaturing conditions; and

identifying a polynucleotide target sequence in the analyte by monitoring changes in the fluorescence signal of the more than one copy during exposure to the denaturing conditions.

24. The method of claims 1 to 19, wherein prior to step (a), the analyte is divided into more than one reaction volume, each volume having a different probe oligonucleotide a introduced₀To detect different target sequences.

25. The method of claims 20 to 24, wherein different probes a₀Comprising a common priming site allowing one or a set of primers to be used for the amplification of step (d).

Summary of The Invention

We have now developed a new method based on the experience of using the pyrophosphorolysis method used in our earlier sequencing patent (see for example WO 2016012789) to overcome many of these limitations. For this purpose, it exploits the double-strand specificity of pyrophosphorolysis; i.e., pyrophosphorolysis reactions will not be effective on single-stranded oligonucleotide substrates or double-stranded substrates containing blocking groups or nucleotide mismatches. Thus, according to the present invention, there is provided a method of detecting a target polynucleotide sequence in a given nucleic acid analyte, characterised by the steps of:

a. annealing of analyte to Single Strand Probe oligonucleotide A₀To produce a double-stranded DNA sequence which is at least partially double-stranded and in which A₀Forms a double-stranded complex with the analyte target sequenceA first intermediate product of a compound;

b. pyrophosphorolysis enzyme (pyrophosphorolysis enzyme) from A₀Is pyrophosphorolysis of the first intermediate product in the 3 '-5' direction to produce partially digested strand A₁And an analyte;

c. (i) mixing A with₁Annealing to a single stranded trigger oligonucleotide B and extending A in the 5 '-3' direction against B₁A chain; or (ii) by a linkage A₁Cyclizing the 3 'and 5' termini thereof; or (iii) A₁Is ligated to the 5' end of the ligation probe oligonucleotide C; in each case generating oligonucleotides A₂；

d. Priming A with at least one Single-Strand primer oligonucleotide₂And produce A₂Or A₂More than one copy of the region of (a); and

e. detecting signals derived from more than one copy and inferring therefrom the presence or absence of the polynucleotide target sequence in the analyte.

Analytes to which the methods of the invention can be applied are those nucleic acids that comprise the target polynucleotide sequence sought, such as naturally occurring or synthetic DNA or RNA molecules. In one embodiment, the analyte is typically present in an aqueous solution containing the analyte and other biological materials, and in one embodiment, the analyte will be present with other background nucleic acid molecules that are not of interest for testing purposes. In some embodiments, the analyte will be present in low amounts relative to these other nucleic acid components. Preferably, for example, when the analyte is derived from a biological sample containing cellular material, some or all of these other nucleic acids and foreign biological material will be removed using sample preparation techniques such as filtration, centrifugation, chromatography or electrophoresis prior to performing step (a) of the method. Suitably, the analyte is derived from a biological sample, such as blood, plasma, sputum, urine, skin or biopsy, taken from a mammalian subject, particularly a human patient. In one embodiment, the biological sample will be lysed to release the analyte by disrupting any cells present. In other embodiments, the analyte may already be present in the sample itself in free form; such as cell-free DNA circulating in blood or plasma.

Brief Description of Drawings

FIG. 1: gel electrophoresis image of the reaction product of example 1. It can be seen that in the presence of oligonucleotide 2, oligonucleotide 1 is degraded to the length at which it is melted from oligonucleotide 2, leaving a shortened oligonucleotide of about 50 nucleotides in length. In contrast, in the presence of oligonucleotide 3, pyrophosphorolysis was not observed due to a single nucleotide mismatch at the 3' end of oligonucleotide 1. In the presence of oligonucleotides 4-6, oligonucleotide 1 pyrophosphorolysis proceeds to the single base mismatch position, in which pyrophosphorolysis stops, leaving the short oligonucleotide without further degradation.

FIG. 2: gel electrophoresis image of the reaction product of example 2. It can be seen that the shortened oligonucleotide (oligonucleotide 1) is effectively circularized by ligation and survives subsequent exonuclease digestion, while the non-shortened oligonucleotide (oligonucleotide 2) is not circularized and is effectively digested.

FIG. 3: gel electrophoresis image of the reaction product of example 3. It can be seen that when shortened oligonucleotides are present and circularised in example 2, a large amount of product is produced by this amplification. In contrast, when the non-shortened oligonucleotide was present and no circularization occurred in example 2, there was no observable DNA amplification.

FIG. 4: fluorescence traces measured as described in example 4. It can be seen that pyrophosphorolysis occurs in the presence of pyrophosphoric acid (pyrophosphate) or iminodiphosphoric acid (imidodiphosphate), but pyrophosphorolysis does not occur in the absence of pyrophosphoric acid or iminodiphosphoric acid. Similarly, in a comparative experiment in which no polymerase was present, no fluorescent signal was generated. Pyrophosphorolysis in the presence of pyrophosphate produces free nucleotide triphosphates, whereas pyrophosphorolysis in the presence of iminodiphosphate produces modified free nucleotide triphosphates (2 '-deoxynucleoside-5' - [ (β, γ) -imino ] triphosphates) in which the O between the β and γ phosphates is replaced by an N — H group.

FIG. 5: example 5, rolling circle amplification from melting peak results of amplification products produced by rolling circle amplification using primers directed against three different mutations that may occur in the EGFR gene: (i) T790M (exon 20), (ii) C797S (exon 20) and (iii) L861Q (exon 21). The temperature was raised to 95 ℃ and measurements were taken at 0.5 ℃ intervals. In (iv), the position of the melting peak can be used to identify which mutation is present, i.e., T790M, C797S, or L861Q.

FIG. 6: as described in example 7, single well 10 retests of Epidermal Growth Factor Receptor (EGFR) exon 19 mutations at 0.1% and 0.5% Mutant Allele Frequencies (MAFs): signal results relative to Wild Type (WT).

FIG. 7: as described in example 7, for simultaneous detection and identification of 0.1% and 1% of T790M (i) and C797S (ii) EGFR mutations in a single well in two colors: signal results relative to wild type.

FIG. 8: (i) the signal observed in the presence of the L858R EGFR mutation from the assay probe and the control probe, relative to wild-type, as described in example 8, and (ii) the result of subtracting the control probe signal from the signal of the assay probe for each sample.

FIG. 9: one embodiment of steps a to b of the process of the invention. In step a, the single-stranded probe oligonucleotide A₀Annealing to a target polynucleotide sequence to produce a polypeptide which is at least partially double stranded and wherein A₀Forms a first intermediate product of a double-stranded complex with the target polynucleotide sequence. In this simplified embodiment of the invention, there are two types of A₀Molecules and a target polynucleotide sequence to account for A not annealing to the target₀How not to participate in the further steps of the method. In this illustrative example of step a, A₀Anneals to the target polynucleotide sequence, and A₀Does not anneal to the target polynucleotide sequence. A. the₀The 5 'terminus of (a) includes a 5' chemical blocking group, a common priming sequence, and a barcode region.

In step b, the partially double-stranded first intermediate is isolated from A by pyrophosphorolysis enzyme₀Pyrophosphorolysis of 3' end in 3' -5 ' direction to produce a moietyDigested chain A₁Analyte and undigested A which does not anneal to target in step a₀A molecule.

FIG. 10: one embodiment of steps c (i) and d of the process of the invention. In step c (i), A₁Annealing to a single stranded trigger oligonucleotide B, and A₁The strand is extended in the 5 '-3' direction against B to produce oligonucleotide A₂. In this illustrative example, trigger oligonucleotide B has a 5' chemical block. Undigested A from step b of the process₀Annealing to trigger oligonucleotide B, however it cannot be extended in the 5 '-3' direction against B to generate a sequence that is the target of the amplification primer of step d.

In step d, A₂Priming with at least one single-stranded primer oligonucleotide and generating A₂Or A₂More than one copy of the region of (a).

FIG. 11: one embodiment of steps c (ii) and d of the process of the invention. In step c (ii), A₁Annealed to the splint oligonucleotide (Splint oligonucleotide) D and then circularized by ligating its 3 'and 5' ends. In step d, the now circularised A is primed with at least one single stranded primer oligonucleotide₂And produce A₂Or A₂More than one copy of the region of (a). In this illustrative example, the 3 '-end and A are modified due to a 3' -modification (chemical modification in this example) or by D₂The splint oligonucleotide D cannot be directed against A₁And (4) extending.

In step d, A₂Priming with at least one single-stranded primer oligonucleotide and generating A₂Or A₂More than one copy of the region of (a).

FIG. 12: one embodiment of steps c (iii) and d of the process of the invention. In step c (iii), the 3' region of splint oligonucleotide D anneals to A₁And the 5 'region of splint oligonucleotide D anneals to the 5' region of ligation probe C. Thus, a second intermediate product A is formed₂Second intermediate product A₂Comprises A₁C and optionally A₁Extending in the 5 '-3' direction toAn intermediate region formed by meeting the 5' end of C. In this illustrative example, ligation probe C has a 3' chemical blocking group, such that 3' -5 ' exonuclease can be used to digest any unligated A prior to the amplification step d₁。

In step d, A₂Priming with at least one single-stranded primer oligonucleotide and generating A₂Or A₂More than one copy of the region of (a).

Detailed Description

According to the present invention there is provided a method of detecting a target polynucleotide sequence in a given nucleic acid analyte, characterised by the steps of:

a. annealing of analyte to Single Strand Probe oligonucleotide A₀To produce a double-stranded DNA sequence which is at least partially double-stranded and in which A₀Forms a first intermediate product of a double-stranded complex with the analyte target sequence;

b. using pyrophosphorolytic enzyme from A₀Is pyrophosphorolysis of the first intermediate product in the 3 '-5' direction to produce partially digested strand A₁And an analyte;

c. (i) mixing A with₁Annealing to a single stranded trigger oligonucleotide B and extending A in the 5 '-3' direction against B₁A chain; or (ii) by a linkage A₁Cyclizing the 3 'and 5' termini thereof; or (iii) A₁Is ligated to the 5' end of the ligation probe oligonucleotide C; in each case generating oligonucleotides A₂；

d. Priming A with at least one Single-Strand primer oligonucleotide₂And produce A₂Or A₂More than one copy of the region of (a); and

e. detecting signals derived from more than one copy and inferring therefrom the presence or absence of the polynucleotide target sequence in the analyte.

Analytes to which the methods of the invention can be applied are those nucleic acids that comprise the target polynucleotide sequence sought, such as naturally occurring or synthetic DNA or RNA molecules. In one embodiment, the analyte is typically present in an aqueous solution containing the analyte and other biological materials, and in one embodiment, the analyte will be present with other background nucleic acid molecules that are not of interest for testing purposes. In some embodiments, the analyte will be present in low amounts relative to these other nucleic acid components. Preferably, for example, when the analyte is derived from a biological sample containing cellular material, some or all of these other nucleic acids and foreign biological material will be removed using sample preparation techniques such as filtration, centrifugation, chromatography or electrophoresis prior to performing step (a) of the method. Suitably, the analyte is derived from a biological sample, such as blood, plasma, sputum, urine, skin or biopsy, taken from a mammalian subject, particularly a human patient. In one embodiment, the biological sample will be lysed to release the analyte by disrupting any cells present. In other embodiments, the analyte may already be present in the sample itself in free form; such as cell-free DNA circulating in blood or plasma.

In one embodiment, the target polynucleotide sequence in the analyte will be a gene or chromosomal region in the DNA or RNA of a cancerous tumor cell, and which is characterized by the presence of one or more mutations; for example in the form of one or more Single Nucleotide Polymorphisms (SNPs). Thus, the present invention would be useful for monitoring disease recurrence. Patients who are declared disease-free after treatment may be monitored over time to detect recurrence of the disease. This needs to be done non-invasively and requires sensitive detection of the target sequence from the blood sample. Also, for some cancers, residual cancer cells remain in the patient after treatment. Monitoring the levels of these cells (or cell-free DNA) present in the blood of a patient using the present invention allows for the detection of recurrence of disease or failure of current therapy and the need to switch to an alternative.

In one embodiment, detection of the target polynucleotide sequence will allow for repeated testing of patient samples during disease treatment to allow for early detection of developed treatment resistance. For example, Epidermal Growth Factor Receptor (EGFR) inhibitors, such as gefitinib, erlotinib, are commonly used as first-line treatments for non-small cell lung cancer (NSCLC). During treatment, tumors often develop mutations in the EGFR gene (e.g., T790M, C797S), which result in resistance to the treatment. Early detection of these mutations allows patients to switch to alternative therapies.

In one embodiment, the target polynucleotide sequence in the analyte will be a gene or chromosomal region in DNA or RNA of fetal origin and characterized by the presence of one or more mutations; for example in the form of one or more Single Nucleotide Polymorphisms (SNPs). Thus, the present invention can be used to detect mutations with very low allele fractions at an earlier stage of pregnancy than other available detection techniques.

In another embodiment, the target polynucleotide sequence may be a gene or genomic region derived from an otherwise healthy individual, but the genetic information obtained may be useful in generating valuable companion diagnostic information that allows medical or therapeutic conclusions to be drawn in one or more defined populations in the human population.

In yet another embodiment, the target polynucleotide sequence may be specific for an infectious disease; such as a polynucleotide sequence specific for a gene or chromosomal region of a bacterium or virus.

In one embodiment, the target polynucleotide sequence may be unique to the donor DNA. When a transplanted organ is rejected by a patient, DNA from the organ is shed into the patient's bloodstream. This early detection of DNA will allow early detection of rejection. This can be achieved using a customized set of donor-specific markers, or by using a set of variants known to be common in a population, some of which will be present in the donor and some in the recipient. Thus, the organ recipient can be routinely monitored over time by the claimed method.

In yet another embodiment, different versions of the method using different combinations of probes and trigger oligonucleotides (see below) are used in parallel, such that more than one target sequence of an analyte can be screened simultaneously; such as a cancer source, a cancer indicator, or more than one infection source. In the method, the amplification products obtained in step (d) are contacted with a detection set comprising one or more oligonucleotide binding dyes or sequence-specific molecular probes such as molecular beacons, hairpin probes or the like by applying the method in parallel. Thus, in another aspect of the invention there is provided the use of at least one probe and optionally one trigger oligonucleotide as defined below in combination with one or more chemical and biological probes selective for a target polynucleotide sequence or the use of at least one probe and optionally one trigger oligonucleotide as defined below in combination with the use of sequencing to identify amplified probe regions.

Step (a) of the method of the invention comprises contacting the analyte whose presence is sought in a given sample with a single-stranded probe oligonucleotide A₀And (6) annealing. In one embodiment, the oligonucleotide comprises a priming region and a 3' terminus that is complementary to a target polynucleotide sequence to be detected. In this way, a first intermediate product is produced that is at least partially double stranded. In one embodiment, this step is carried out in an excess of A₀In an aqueous medium containing the analyte and any other nucleic acid molecules.

In one embodiment, when the molecular probe is to be used for detection in step (e), the probe oligonucleotide A₀Is configured to include an oligonucleotide recognition region on the 5' side of the region complementary to the target sequence, and the molecular probe used is designed to anneal to the recognition region. In one embodiment, only A₀The complementary region of (a) is capable of annealing to the target; that is, any other region lacks sufficient complementarity to the analyte for a stable duplex to be present at the temperature at which step (b) is carried out. Here and throughout, the term "sufficient complementarity" means that, to the extent that a given region has complementarity to a given region on an analyte, the region of complementarity is more than 10 nucleotides long.

In a preferred embodiment, A₀The 5 'end of (a) or an internal site 5' to the priming region is rendered resistant to exonucleolysis. In this way, and after step (b), an exonuclease having 5 '-3' exonucleolytic activity may optionally be added to the reaction medium to digest any other nucleic acid components presentSimultaneously make A₀And chain A comprising partial digestion₁Is complete. Suitably, this resistance to exonucleolysis is provided by the presence of oligonucleotide A₀By introducing one or more blocking groups into the desired site. In one embodiment, these blocking groups may be selected from phosphorothioate linkages (phosphothioate linkages) and other backbone modifications commonly used in the art, C3 spacers, phosphate groups (phosphate groups), modified bases, and the like. In yet another embodiment, A₀There is an oligonucleotide flap mismatch (flap mismatch) with respect to one or both of the 3 'and 5' ends of the trigger oligonucleotide, as will be described further below.

In one embodiment, the identification region will comprise or be embedded in a barcode coding region (barcoding region) having a unique sequence and suitable for use in step (e) with component a for amplification₂The sequence-specific molecular probes of (a) are identified indirectly or directly by sequencing of these components. Examples of molecular probes that may be used include, but are not limited to, molecular beacons,A probe,Probes, and the like.

In step (b) of the process, the double-stranded region of the first intermediate product is separated from its A₀The 3' end of the strand is pyrophosphorolyzed in the 3' -5 ' direction. Thus, A₀The chains are gradually digested, producing partially digested chains; hereinafter referred to as A₁. When the probe oligonucleotide erroneously hybridizes to a non-target sequence, the pyrophosphorolysis reaction will stop at any mismatch, preventing the subsequent steps of the method from proceeding. In another embodiment, this digestion is continued until A₁Lack sufficient complementarity to form a stable duplex with the analyte or target region therein. At this point, the individual strands are then separated by melting, resulting in a single-stranded form of a₁. Under typical conditions of pyrophosphorolysis, the acid is,when the analyte and A₀Between 6 and 20 complementary nucleotides, this separation occurs.

Suitably, the pyrophosphorolysis step (b) is carried out in a reaction medium at a temperature in the range 20 to 90 ℃ in the presence of a polymerase exhibiting pyrophosphorolysis activity and a source of pyrophosphate ion (source of pyrophosphorophosphate ion). Additional information regarding pyrophosphorolysis reactions applied to polynucleotide digestion may be found, for example, in j.biol.chem.244(1969) pp.3019-3028 or our earlier patent application.

In one embodiment, the pyrophosphorolysis step (b) is driven by the presence of an excess of a focused phosphoric acid (polypyrophosphate) source, suitable sources including those compounds containing 3 or more phosphorus atoms.

In one embodiment, the pyrophosphorolysis step (b) is driven by the presence of an excess of a modified pyrophosphate source. Suitable modified pyrophosphates include those in which the bridging oxygen is substituted with another atom or group, or pyrophosphates (or focused phosphates) in which the other oxygen is substituted with a substituent or modifying group. Those skilled in the art will appreciate that there are many examples of such modified pyrophosphates suitable for use in the present invention, and their non-limiting choices are:

in a preferred embodiment, the pyrophosphate ion source is PNP, PCP or tripolyphosphoric acid (PPPi).

Further, but not limited to, examples of pyrophosphate ion sources used in the pyrophosphorolysis step (b) can be found in WO2014/165210 and WO 00/49180.

In one embodiment, the excess modified pyrophosphate source may be represented by Y-H, where Y corresponds to the general formula (X-O)₂P(＝B)-(Z-P(＝B)(O-X))_n-, where n is an integer of 1 to 4; each Z-is independently selected from-O-, -NH-or-CH₂-; each B is independently O or S; x groups are independently selected from-H, -Na, -K, alkyl, alkenyl or heterocyclic groups, with the proviso that when Z andb all correspond to-O-, and when n is 1, at least one X group is not H.

In one embodiment, Y corresponds to the formula (X-O)₂P(＝B)-(Z-P(＝B)(O-X))_n-, where n is 1, 2, 3 or 4. In another embodiment, the Y group corresponds to the formula (X-O)₂P (═ O) -Z-P (═ O) (O-H) -, where one of the X groups is-H. In yet another preferred embodiment, Y corresponds to the formula (X-O)₂P (═ O) -Z-P (═ O) (O-X) -, where at least one of the X groups is selected from methyl, ethyl, allyl, or dimethylallyl.

In an alternative embodiment, Y corresponds to the formula (H-O)₂P (═ O) -Z-P (═ O) (O-H) - (where Z is-NH-or-CH)₂-) or (X-O)₂P (═ O) -Z-P (═ O) (O-X) - (where X groups are all-Na or-K, and Z is-NH-or-CH₂-)。

In another embodiment, Y corresponds to the formula (H-O)₂P (═ B) -O-P (═ B) (O-H) -, where each B group is independently O or S, at least one is S.

Specific examples of preferred embodiments of Y include those of formula (X1-O) (HO) P (═ O) -Z-P (═ O) (O-X2), wherein Z is O, NH or CH₂And (a) X1 is γ, γ -dimethylallyl, and X2 is-H; or (b) both X1 and X2 are methyl; or (c) both X1 and X2 are ethyl; or (d) X1 is methyl and X2 is ethyl, or vice versa.

In one embodiment, step (b) is carried out in the presence of a phosphatase to remove continuously by hydrolysis of nucleoside triphosphates produced by the pyrophosphorolysis reaction. In another embodiment, pyrophosphatase is added after step (b) to hydrolyze any remaining pyrophosphate ions (pyrophosphorolysis) to ensure that no further pyrophosphorolysis will occur in subsequent steps. In another embodiment, steps (a) and (b) are iterated such that more than one copy of a is produced from each target molecule₁. This may occur before or simultaneously with the performance of the subsequent steps. When combined with amplification in step (d), such iterations result in further improving the sensitivity and reliability of the method and allow for the targeting of polynucleotides by introducing an initial linear amplificationMore accurate quantification.

In a preferred but not essential embodiment, at the end of step (b) or before or after step (c), an intermediate step is introduced in which an exonuclease active in the 5 '-3' direction is added, in order to ensure that it contains, in addition to A₀Or A₁Any residual nucleic acid species present, other than the nucleic acid species of the strand (where the 5' blocking group is present), are destroyed. In another embodiment, the exonuclease is inactivated prior to performing step (d). In yet another embodiment, prior to or simultaneously with performing the exonuclease, all of the nucleic acid material present is phosphorylated at its 5' end using, for example, a kinase and a phosphate donor (such as ATP) to generate a phosphorylated end site required for initiation of the exonuclease by certain types of 5' -3 ' exonucleases.

After step (b), or in a related intermediate step described above, in one embodiment (i), A₁Annealing to the single stranded trigger oligonucleotide B to produce a second intermediate product that is also partially double stranded. In one embodiment, B comprises a and A₁The 3 '-terminal complementary oligonucleotide region of (A) having at its 5' -terminal the sequence of₀A substantially non-complementary flanking oligonucleotide region. Here and throughout, the term "not substantially complementary" or equivalent language means that, for a given flanking region and A, the same₀The given region above has complementarity, the region of complementarity is less than 10 nucleotides long. Thereafter, in step (c), A of the second intermediate product₁The strand is extended in the 5 '-3' direction to produce a third intermediate product comprising B and an extended A₁Chain (hereinafter referred to as A)₂)。

In another embodiment, B comprises (i) and A₁An oligonucleotide region complementary to the 3' terminus of (a); (ii) and A₁(ii) and optionally (iii) an intermediate oligonucleotide region between the two regions, and wherein B is not accessible to a by the presence of one or more nucleotide mismatches or chemical modifications at its 3' terminus₁Is used to extend. In another embodiment, B is at 3 'thereof'Both the ends and the interior are modified to prevent other oligonucleotides from extending against it.

In both embodiments, B suitably comprises oligonucleotide regions, each oligonucleotide region independently being up to 150 nucleotides in length, typically 5 to 100 nucleotides in length, and most preferably 10 to 75 nucleotides in length. In one embodiment, all regions of B independently have a length in the range of 10 to 50 nucleotides. In another preferred embodiment, the 5' end of B or a region adjacent thereto is also protected with a blocking group of the type described above to render it resistant to exonucleolytic cleavage. In some embodiments, the 5' end of B is folded upon itself to form a double-stranded hairpin region. In yet another embodiment, both the 3 'and 5' ends of B are linked to its A₁The corresponding strand has one or more nucleotide mismatches at its end.

In another embodiment, step (c) optionally comprises (ii) subjecting A to the presence of a ligase₁Are linked together to produce a third intermediate, wherein A₁The strand is not extended but cyclized. This ligation is usually performed by adding a splint oligonucleotide D having a chemical bond to A₁Such that when annealed to D, A₁Forming a nick that can be ligated or filled in prior to subsequent ligation. In this embodiment, for the purpose of the subsequent step, cyclized A₁Becomes actually A₂. In another embodiment, a polymerase lacking 5 '-3' exonuclease and strand displacement activity is used, A₁The strand is still extended in the 5 '-3' direction and then cyclized, so that the product of the extension and cyclization becomes in fact A₂. In another embodiment, A₁Or extended A₁Are linked together via a bridging group, which does not necessarily comprise the oligonucleotide region.

Comprising cyclised A in a third intermediate₂In the case of strands, the reaction mixture produced in step (c) is treated with an exonuclease or a combination of exonucleases to digest any residual unclyclized nucleiThe acid component is advantageous. Thereafter, in another embodiment, the exonuclease is inactivated before step (d) occurs.

In another embodiment (iii), step (C) is performed in the presence of a ligation probe C having a 5 'region complementary to at least a portion of the 5' terminal region of the splint oligonucleotide D or to the target oligonucleotide, a ligase, and optionally a polymerase lacking both strand displacement capability and 5 '-3' direction exonuclease activity. In this way, a second intermediate product is formed, in which A₂The chain comprising A₁C and optionally A₁An intermediate region extending in the 5' -3 ' direction to meet the 5' -end of the C. In this embodiment, the primers used in step (d) (see below) are selected to amplify A₂Comprises that A has occurred₁Site of attachment to C. In this embodiment, we have found that it is advantageous to include a 3' blocking group on C so that the 3' -5 ' exonuclease can be used to digest any unligated A prior to amplification₁. Suitable polymerases that may be used include, but are not limited to, Hemo KlenaQ, Mako, and Stoffel fragments.

In one embodiment, when steps c (ii) or c (iii) are employed, A₁Optionally extended in the 5 '-3' direction prior to ligation. In one embodiment, this optional extension and ligation is performed on the target oligonucleotide, while in another embodiment they are performed by adding another splint oligonucleotide D, A₁Annealing to splint oligonucleotide D prior to extension and/or ligation. In one embodiment, D comprises a and A₁And an oligonucleotide region complementary to the 3 'terminus of oligonucleotide C and the 5' terminus or A₁A region complementary to the 5' end of (a). In another embodiment, the 3' terminus is modified by the 3' terminus or by the 3' terminus of D and A₁Of the corresponding region of (A), D cannot be directed against A₁And (4) extending.

In a subsequent step (d), A is reacted₂The strand or desired region thereof undergoes amplification, producing more than one copy, typically millions of copies. This is achieved byPriming of A with Single-stranded primer oligonucleotides₂And any amplicon subsequently derived from a2, said single stranded primer oligonucleotide being provided, for example, in a forward/reverse or sense/antisense pair, which may anneal to a region of a2 and a complementary region on any amplicon subsequently derived from a 2. The primed strand then becomes the origin of amplification. Amplification methods include, but are not limited to, thermal cycling and isothermal methods, such as polymerase chain reaction, recombinase polymerase amplification, and rolling circle amplification; when A is₂When cyclized, the last term applies. By any of these methods, A₂Many amplicon copies of (a) and in some cases its sequence complement can be generated rapidly. The exact method of performing any of these amplification methods is well known to the ordinarily skilled artisan and the exact conditions and temperature patterns employed are readily available in the general literature as read by the reader. In particular, in the case of Polymerase Chain Reaction (PCR), the method typically involves targeting a in the 5 '-3' direction to a using a polymerase and a source of a plurality of mononucleoside triphosphates₂Extending the primer oligonucleotide until a complementary strand is produced; dehybridization of the resulting double-stranded product to regenerate A₂A strand and a complementary strand; reinitiation of A₂The strand and any amplicons thereof, and then repeating these extension/de-hybridization/re-priming steps multiple times to convert A₂The concentration of the amplicon is established to a level where it can be reliably detected.

Finally, in step (e), the amplicons are detected and the information obtained is used to infer whether the polynucleotide target sequence is present in the original analyte and/or a property associated therewith. In this way, for example, a target sequence specific to a cancerous tumor cell can be detected with reference to the particular SNP being sought. In another embodiment, target sequences specific to the viral or bacterial genome (including novel mutations thereof) may be detected. A number of methods of detecting the amplicon or recognition region can be used, including, for example, oligonucleotide binding dyes, sequence-specific molecular probes such as fluorescently labeled molecular beacons or hairpin probes. Alternatively, A₂Direct sequencing of amplicons can be performed using one of the direct sequencing methods employed or reported in the artTo proceed with. When using oligonucleotide binding dyes, fluorescently labeled beacons or probes, it is convenient to detect amplicons using an arrangement comprising a source of stimulating electromagnetic radiation (laser, LED, lamp, etc.) and a photodetector arranged to detect the emitted fluorescence and generate therefrom a signal comprising a data stream that can be analyzed by a microprocessor or computer using a specially designed algorithm.

In one embodiment of the invention, more than one A is used₀Probes, each probe selective for a different target sequence, and each probe comprising a recognition region. In one embodiment, the region subsequently amplified in step (d) comprises the recognition region. In another embodiment, the amplicons generated in step (d) are then deduced by detecting the recognition region. Identification may then involve the use of molecular probes or sequencing methods, such as Sanger sequencing,Sequencing or one of the methods we have previously described. In another manifestation, prior to step (a), the analyte is divided into more than one reaction volume, each volume having a different probe oligonucleotide A₀Or more than one probe oligonucleotide A designed to detect different target sequences₀. In another preferred embodiment, different probes A₀Comprising a common priming site allowing one or a set of primers to be used for amplification step (d).

In some embodiments, the amplifying step (d) may be performed by standard Polymerase Chain Reaction (PCR) or by isothermal amplification such as Rolling Circle Amplification (RCA). In some embodiments, the RCA may be in the form of exponential RCA, e.g., hyperbranched RCA, which may generate a plurality of double stranded DNA of different lengths. In some embodiments, it may be desirable to provide different probes capable of producing different products having different lengths.

In some embodiments, step (e) further comprises the steps of:

i. fluorescent binding of dyes or molecular probes using one or more oligonucleotidesMark A₂Or A₂More than one copy of the region of (a);

measuring the fluorescence signal of the more than one copy;

exposing the more than one copy to a set of denaturing conditions; and

identifying a polynucleotide target sequence in the analyte by monitoring changes in the fluorescence signal of the more than one copy during exposure to denaturing conditions.

In some embodiments, step (e) may take the form of detection and analysis using melting curve analysis. Melting curve analysis can be used as an assessment of the dissociation properties of double stranded DNA during heating. The temperature at which 50% of the DNA in a sample is denatured into two separate strands is called the melting temperature (Tm). As temperature increases, the duplexes begin to dissociate, with different double-stranded DNA molecules dissociating at different temperatures based on composition (G-C base pairs have 3 hydrogen bonds, and only 2 between a-T — thus G-C requires a higher temperature than a-T to separate), length (longer double-stranded DNA with more hydrogen bonds requires a higher temperature than shorter strands to dissociate completely into two separate single strands), and complementarity (DNA molecules with a large number of mismatches have a lower Tm due to fewer hydrogen bonds between matching base pairs).

In some embodiments, the amplifying step (d) may be performed in the presence of an intercalating fluorescent agent. Thus, when melting curve analysis is performed, changes in fluorescence are monitored, which are indicative of the Tm (and thus identity) of the reaction product, and thus of the target polynucleotide sequence. The change in fluorescence can be detected using an arrangement comprising a source of stimulating electromagnetic radiation (laser, LED, lamp, etc.) and a photodetector arranged to detect the emitted fluorescence and generate therefrom a signal comprising a data stream that can be analyzed by a microprocessor or computer using a specially designed algorithm.

The intercalating fluorescent agent may be a dye specific for double stranded DNA, such as SYBR Green (SYBR Green), EvaGreen, LG Green (LG Green), LC Green plus (LC Green plus), ResoLight, Chromofy, or SYTO 9. Those skilled in the art will appreciate that there are many embedded phosphors that can be used in the present invention, and the above list is not intended to limit the scope of the invention. The intercalating fluorescent agent can be a fluorescently labeled DNA probe. In one embodiment of the invention, juxtapositioned probes (probes), one probe comprising a fluorophore and the other probe comprising a suitable quencher, can be used to determine the complementarity of the DNA probe to the target amplification sequence.

In another aspect of the invention, there is provided a method of identifying a target polynucleotide sequence in a given nucleic acid analyte, characterised by the steps of:

a. annealing of nucleic acid analytes to Single Strand Probe oligonucleotide A₀To produce a double-stranded DNA sequence which is at least partially double-stranded and in which A₀Forms a first intermediate product of a double-stranded complex with the analyte target sequence;

b. using pyrophosphorolytic enzyme from A₀Is pyrophosphorolysis of the first intermediate product in the 3 '-5' direction to produce partially digested strand A₁And an analyte;

c. (i) mixing A with₁Annealing to a single stranded trigger oligonucleotide B and extending A in the 5 '-3' direction against B₁A chain; or (ii) by a linkage A₁Cyclizing the 3 'and 5' termini thereof; or (iii) A₁Is ligated to the 5' end of the ligation probe oligonucleotide C; in each case generating oligonucleotides A₂；

d. Priming A with at least one Single-Strand primer oligonucleotide₂And produce A₂Or A₂More than one copy of the region of (a);

e. labelling A with one or more oligonucleotide fluorescent binding dyes or molecular probes₂Or A₂More than one copy of the region of (a);

f. measuring the fluorescence signal of more than one copy;

g. exposing more than one copy to a set of denaturing conditions; and

h. the target polynucleotide sequence is identified by monitoring the change in the fluorescent signal of more than one copy during exposure to denaturing conditions.

In some embodiments, denaturing conditions may be provided by varying the temperature, for example raising the temperature to a point where the double strand begins to dissociate. Additionally or alternatively, denaturing conditions may also be provided by changing the pH to make the conditions acidic or basic, or by adding additives or reagents such as strong acids or bases, concentrated inorganic salts, or organic solvents such as alcohols.

In another aspect of the invention, which may be used in conjunction with or independently of the method of the first aspect, the analyte in single stranded form may be prepared from the biological sample described above by a series of preliminary steps designed to amplify the analyte and isolate it from background genomic DNA, which is typically present in significant excess. The method is generally applicable to the generation of single-stranded target analytes, and thus the method is useful in addition to being integrated with or further comprising a part of the method of the first aspect of the invention. Accordingly, there is provided a method for preparing at least one single stranded analyte of nucleic acid comprising a target polynucleotide region, characterized by the steps of: (i) amplicons of the analyte are generated by subjecting a biological sample comprising the corresponding double-stranded form of the analyte and optionally background genomic DNA to an amplification cycle. In a preferred embodiment, amplification is carried out using a Polymerase Chain Reaction (PCR) in the presence of a polymerase, nucleotide triphosphates and at least one corresponding primer pair, wherein one primer comprises a 5 '-3' exonuclease blocking group, and (ii) optionally digesting the product of step (i) with an exonuclease having 5 '-3' exonuclease activity. In one embodiment, the method may further comprise (iii) reacting the product of step (ii) with a protease to disrupt the polymerase, and then (iv) inactivating the protease by heating the product of step (iii) to a temperature in excess of 50 ℃.

In a preferred embodiment, steps (i) to (iv) are carried out prior to step (1) of the method of the first aspect of the invention to produce an integrated method of detecting a target sequence derived from a biological sample. In another embodiment, the biological sample has undergone cell lysis prior to performing step (i).

In one embodiment of step (i), the nucleoside triphosphateAcids are a mixture of the four deoxynucleoside triphosphates characteristic of naturally occurring DNA. In a preferred embodiment, the mixture of deoxynucleoside triphosphates comprises deoxyuridine triphosphate (dUTP) instead of deoxythymidine triphosphate (dTTP), and step (i) is also carried out in the presence of dUTP-DNA glycosylase (UDG) to remove any contaminating amplicons from a previous assay. In yet another embodiment, a high fidelity polymerase is used in step (i), e.g.under the trademark HiOr one of those sold under Q5.

In one embodiment, step (i) is performed using a limited number of primers and an excess of amplification cycles. In this way, a fixed amount of amplicon is produced regardless of the initial amount of analyte. Thus, the need to quantify the analyte prior to a subsequent step is avoided. In another embodiment of step (i), it is advantageous that step (ii) is not required and amplification is carried out in the presence of a primer pair in which one of the two primers is present in excess of the other, once one primer is fully utilised, resulting in the production of a single stranded amplicon.

In a preferred embodiment of step (ii), the 5' primer is blocked with an exonuclease blocking group selected from the group consisting of phosphorothioate linkages, inverted bases (inverted bases), DNA spacers and other oligonucleotide modifications well known in the art. In another embodiment, the other primer of the pair of primers has a phosphate group at its 5' end.

In one embodiment, the protease used in step (iii) is proteinase K and step (iv) is performed by heating to a temperature of 80 to 95 ℃ for up to 30 minutes. In another embodiment, at some time after step (ii) but before step (b), the reaction medium is treated with apyrase (apyrase) or other phosphatase to remove any residual nucleoside triphosphates that may be present.

In another aspect of the invention, an alternative embodiment is provided wherein the phospholysis step (b) is replaced by an exonuclease digestion step using a double strand specific exonuclease. Those skilled in the art will appreciate that double-strand specific exonucleases include those that read in the 3 '-5' direction, such as ExoIII, and those that read in the 5 '-3' direction, such as Lambda Exo, among others.

In one embodiment of this aspect, the double strand specific exonuclease of step (b) is carried out in the 3 '-5' direction. In such embodiments, the method of the invention is characterized by the steps of:

a. annealing of analyte to Single Strand Probe oligonucleotide A₀To produce a double-stranded DNA sequence which is at least partially double-stranded and in which A₀Forms a first intermediate product of a double-stranded complex with the analyte target sequence;

b. from A with double-strand specific exonuclease₀Digesting the first intermediate in the 3 '-5' direction to produce partially digested strand A₁And an analyte;

c. (i) mixing A with₁Annealing to a single stranded trigger oligonucleotide B and extending A in the 5 '-3' direction against B₁A chain; or (ii) linking A₁Cyclizing the 3 'and 5' termini thereof; or (iii) A₁Is ligated to the 5' end of the ligation probe oligonucleotide C; in each case generating oligonucleotides A₂；

d. Priming A with at least one Single-Strand primer oligonucleotide₂And produce A₂Or A₂More than one copy of the region of (a); and

e. detecting signals derived from more than one copy and inferring therefrom the presence or absence of the polynucleotide target sequence in the analyte.

In one embodiment of this aspect, the double strand specific exonuclease of step (b) is carried out in the 5 '-3' direction. In such embodiments, the method of the invention is characterized by the steps of:

a. annealing of analyte to Single Strand Probe oligonucleotide A₀To be produced as at least partially double stranded and whichIn A₀Forms a first intermediate product of a double-stranded complex with the analyte target sequence;

b. from A using a double-strand specific exonuclease₀Digesting the first intermediate product in the 5 '-3' direction to produce a partially digested strand A₁And an analyte;

c. (i) mixing A with₁Annealing to a single stranded trigger oligonucleotide B and extending A in the 5 '-3' direction against B₁A chain; or (ii) by a linkage A₁Cyclizing the 3 'and 5' termini thereof; or (iii) A₁Is ligated to the 3' end of the ligation probe oligonucleotide C; in each case generating oligonucleotides A₂；

d. Priming A with at least one Single-Strand primer oligonucleotide₂And produce A₂Or A₂More than one copy of the region of (a); and

e. detecting signals derived from more than one copy and inferring therefrom the presence or absence of the polynucleotide target sequence in the analyte.

In an embodiment of the invention, wherein step (b) utilizes a double strand-specific 5 '-3' exonuclease, A₀Is complementary to the target analyte, and the common trigger sequence and blocking group are located on the 3' side of the region complementary to the target. In another embodiment, when the molecular probe is to be used for detection in step (e), the probe oligonucleotide A₀Is configured to include an oligonucleotide recognition region on the 3' side of the region complementary to the target sequence, and the molecular probe used is designed to anneal to the recognition region.

In embodiments of the invention in which step (b) utilises a double-strand specific 5 '-3' exonuclease, after step b an exonuclease having 3 'to 5' exonuclease activity may optionally be added to the reaction mixture to digest any other nucleic acid molecules present whilst allowing a to pass₀And chain A comprising partial digestion₁Any material of (a) remains intact. Suitably, such resistance to exonucleolysis is obtained as previously described.

It should be understood that by using more than oneAt a different A₀And optionally B, C or a D component, the methods of the invention can be applied to reaction mixtures containing more than one different analyte, each component associated with a different molecular probe or the like. In such a multiplexing method, more than one target region unique to a specific cancer or a plurality of infectious diseases or the like is enabled to be detected. In one embodiment, it is preferred that each different A is generated₂The strands have a common primer site but different recognition regions, enabling one or a set of primers to be used in the amplification step (d).

In another aspect of the invention, there is provided the use of the above method to screen a mammalian subject, particularly a human patient, for the presence of an infectious disease, cancer or to generate concomitant diagnostic information.

In another aspect of the invention, a control probe for use in the above method is provided. Embodiments of the invention include those in which the presence of one or more specific target sequences is elucidated by generating a fluorescent signal.

In such embodiments, there may inevitably be signal levels generated by non-target DNA present in the sample. For a given sample, the background signal is later than the onset time of the "true" signal, but such onset may differ between samples. Thus, accurate detection of the presence of low concentrations of one or more than one target sequence depends on knowledge of what signal is expected in the absence of the target sequence. For human samples (conditioned samples), the reference is available, but not for true "blind" samples from patients. Control Probe (E)₀) For determining the expected background signal characteristics for each assay probe. The control probe targets sequences that are not expected to be present in the sample, and the signal generated from that probe can then be used to infer the expected rate of signal generation from the sample in the absence of the target sequence.

Accordingly, there is provided a method of detecting a target polynucleotide sequence in a given nucleic acid analyte, characterised by the steps of:

a. single-stranded Probe oligonucleotide A₀Is added to the sampleTo anneal with a target analyte to produce a second nucleic acid molecule that is at least partially double-stranded and wherein A₀Forms a first intermediate product of a double-stranded complex with the analyte target sequence;

b. using pyrophosphorolytic enzyme from A₀Is pyrophosphorolysis of the first intermediate product in the 3 '-5' direction to produce partially digested strand A₁And an analyte;

c. (i) mixing A with₁Annealing to a single stranded trigger oligonucleotide B and extending A in the 5 '-3' direction against B₁A chain; or (ii) by a linkage A₁Cyclizing the 3 'and 5' termini thereof; or (iii) A₁Is ligated to the 5' end of the ligation probe oligonucleotide C; in each case generating oligonucleotides A₂；

d. Priming A with at least one Single-Strand primer oligonucleotide₂And produce A₂Or A₂More than one copy of the region of (a);

e. detecting signals originating from more than one copy;

f. subsequently or simultaneously, using a separate aliquot of the sample or in the same aliquot and using a second detection channel, using a second single-stranded probe oligonucleotide E₀Repeating steps (a) to (E), the second single-stranded probe oligonucleotide E₀A 3' terminal region having at least a partial mismatch with the target sequence;

g. inferring from the results of (f) what would be expected from A in the absence of any target analyte in the sample₀The generated background signal; and

h. inferring the presence or absence of the polynucleotide target sequence in the analyte by comparing the expected background signal inferred in (g) with the actual signal observed in (e).

In some embodiments, the method in step (e) according to the invention occurs by:

i. labelling A with one or more oligonucleotide fluorescent binding dyes or molecular probes₂Or A₂More than one copy of the region of (a);

measuring the fluorescence signal of more than one copy produced in step (d);

exposing more than one copy to a set of denaturing conditions; and

detecting the presence and identification of amplified products by monitoring the change in fluorescence signal of more than one copy during exposure to denaturing conditions, as compared to the same measurement performed on the products of step (f).

In one embodiment, a control probe (E)₀) And A₀Is added to a different portion of the sample, while in another embodiment, E₀And A₀Are added to the same portion of the sample and different detection channels (e.g., different color dyes) are used to measure their respective signals. E can then be utilized₀The signal generated to infer and correct for the expected A in the absence of the polynucleotide target sequence in the sample₀The generated background signal. For example, the correction of the background signal may include a correction from A₀Subtracting the observed signal from E₀Observed signal, or by using A₀And E₀Calibrating the slave A with calibration curves of the relative signals generated under different conditions₀The observed signal.

In one embodiment, an E may be used₀To calibrate all assay probes that may be generated.

In one embodiment, E alone may be used₀To calibrate each amplicon of the sample DNA generated in the initial amplification step. Each amplicon may contain more than one mutation/target sequence of interest, but a single E₀It is sufficient to calibrate all assay probes to a single amplicon.

In another embodiment, separate E's may be used for each target sequence₀. For example, if C>T mutations are targeted, and an E can be designed₀Targeting C at the same site that is not known to exist in the patient>And G mutation. E₀The signal curves generated under a variety of conditions can be evaluated in a calibration reaction, and these data used to infer that when the variant is absent, from target C>Predicted signal of assay probe for T variant.

In the figureOne embodiment of the process of the present invention can be seen in figures 9 to 12. In fig. 9, one embodiment of steps a to b is shown. In step a, the single-stranded probe oligonucleotide A₀Annealing to a target polynucleotide sequence to produce a polypeptide which is at least partially double stranded and wherein A₀Forms a first intermediate product of a double-stranded complex with the target polynucleotide sequence. In this simplified embodiment of the invention, there are two A' s₀Molecules and a target polynucleotide sequence to account for A not annealed to the target₀How not to participate in the further steps of the method. In this illustrative example of step a, A₀Anneals to the target polynucleotide sequence, and A₀Does not anneal to the target polynucleotide sequence. A. the₀The 5 'terminus of (a) includes a 5' chemical blocking group, a common priming sequence, and a barcode region.

In step b, the partially double-stranded first intermediate is separated from A by pyrophosphorolytic enzyme₀Pyrophosphorolysis of 3' end in 3' -5 ' direction to produce partially digested strand A₁Analyte and undigested A which does not anneal to target in step a₀A molecule.

In fig. 10, an embodiment of steps c (i) to d is shown. In step c (i), A₁Annealing to a single stranded trigger oligonucleotide B, and A₁The strand is extended in the 5 '-3' direction against B to produce oligonucleotide A₂. In this illustrative example, trigger oligonucleotide B has a 5' chemical block. Undigested A from step b of the process₀Annealing to trigger oligonucleotide B, however it cannot be extended in the 5 '-3' direction against B to generate a sequence that is the target of the amplification primer of step d.

In step d, A₂Priming with at least one single-stranded primer oligonucleotide and generating A₂Or A₂More than one copy of the region of (a).

In fig. 11, an embodiment of steps c (ii) to d is shown. In step c (ii), A₁Annealed to splint oligonucleotide D and then circularized by ligating its 3 'and 5' ends. In step d, the oligonucleotide is primed with at least one single-stranded primerNucleotide priming of now cyclized A₂And produce A₂Or A₂More than one copy of the region of (a). In this illustrative example, the 3 '-end and A are modified due to a 3' -modification (chemical modification in this example) or by D₂The splint oligonucleotide D cannot be directed against A₁And (4) extending.

In step d, A₂Priming with at least one single-stranded primer oligonucleotide and generating A₂Or A₂More than one copy of the region of (a).

In fig. 12, an embodiment of steps c (iii) to d is shown. In step c (ii), A₁Annealed to splint oligonucleotide D and then circularized by ligating its 3 'and 5' ends. In step d, the now circularised A is primed with at least one single stranded primer oligonucleotide₂And produce A₂Or A₂More than one copy of the region of (a). In this illustrative example, the 3 '-end and A are modified due to a 3' -modification (chemical modification in this example) or by D₂The splint oligonucleotide D cannot be directed against A₁And (4) extending.

In step d, A₂Priming with at least one single-stranded primer oligonucleotide and generating A₂Or A₂More than one copy of the region of (a).

Specificity of the method of the invention may be promoted by blocking at least a portion of the wild type DNA₀Annealing only to the target polynucleotide sequence. Blocking oligonucleotides can be used to improve the specificity of Polymerase Chain Reaction (PCR). A commonly used technique is to design an oligonucleotide that anneals between PCR primers and cannot be replaced or digested by a PCR polymerase. Oligonucleotides are designed to anneal to non-target (usually healthy) sequences, but to mismatch (usually differ by a single base) to target (mutated) sequences. This mismatch results in a difference in melting temperatures for the two sequences, and the oligonucleotide is designed to remain annealed to the non-target sequence while dissociating from the target sequence at the PCR extension temperature.

The blocking oligonucleotide may typically have a modification to prevent it from being digested by the exonuclease activity of the PCR polymerase, or to increase the melting temperature difference between the target and non-target sequences.

The incorporation of Locked Nucleic Acids (LNA) or other melting temperature altering modifications in blocking oligonucleotides can significantly increase the difference in melting temperature of the oligonucleotide for target and non-target sequences.

Accordingly, embodiments of the invention are provided in which blocking oligonucleotides are used. Blocking oligonucleotides must be resistant to pyrophosphorolysis (PPL) reactions to ensure that they are not digested or replaced. This can be achieved in a number of different ways, for example by a mismatch at the 3' end or by modifications such as phosphorothioate linkages or spacers.

In such embodiments or aspects of the invention using blocking oligonucleotides, the method of detecting a target polynucleotide sequence in a given nucleic acid analyte is characterized by the steps of:

a. annealing single-stranded blocking oligonucleotides to at least a subset of the non-target polynucleotide sequences;

b. annealing of analyte target sequence to Single Strand Probe oligonucleotide A₀To produce a double-stranded DNA sequence which is at least partially double-stranded and in which A₀Forms a first intermediate product of a double-stranded complex with the analyte target sequence;

c. using pyrophosphorolytic enzyme from A₀Is pyrophosphorolysis of the first intermediate product in the 3 '-5' direction to produce partially digested strand A₁And an analyte;

d. (i) mixing A with₁Annealing to a single stranded trigger oligonucleotide B and extending A in the 5 '-3' direction against B₁A chain; or (ii) by reacting A with₁The 3 'and 5' ends of (a) are ligated to cyclize them; or (iii) A₁Is ligated to the 5' end of the ligation probe oligonucleotide C; in each case generating oligonucleotides A₂；

e. Priming A with at least one Single-Strand primer oligonucleotide₂And produce A₂Or A₂More than one copy of the region of (a); and

f. detecting signals derived from more than one copy and inferring therefrom the presence or absence of the polynucleotide target sequence in the analyte.

In one embodiment, the blocking oligonucleotide becomes resistant to pyrophosphorolysis by virtue of a mismatch at its 3' end. In another embodiment, the blocking oligonucleotide is made tolerant by the presence of a 3' -blocking group. In another embodiment, the blocking oligonucleotide is made tolerant by the presence of a spacer or other internal modification. In another embodiment, the blocking oligonucleotide includes both a modified or modified nucleotide base that increases the melting temperature and becomes resistant to pyrophosphorolysis.

The invention will now be illustrated with reference to the following experimental data.

Example 1: pyrophosphorolysis specificity for single nucleotide mismatches

Preparing a single stranded first oligonucleotide 1(SEQ ID NO 1) having the following nucleotide sequence:

wherein A, C, G and T represent nucleotides carrying the relevant characteristic nucleobases of DNA.

A set of single stranded oligonucleotides 2-6(SEQ ID NOs 2-6) having the following nucleotide sequences in the 5 'to 3' direction were also prepared:

wherein oligonucleotide 2 comprises a 52 base region complementary to the 52 bases at the 3' end of oligonucleotide 1 and oligonucleotides 3-6 comprise the same region having single nucleotide mismatches at positions 1, 10, 20 and 30, respectively.

A reaction mixture was then prepared having a composition corresponding to that obtained from the following formulation:

20uL 5 Xbuffer pH 8.0

10uL oligonucleotide 1, 3000nM

10uL of oligonucleotide 2, 3, 4, 5 or 6, 3000nM

2.5U Mako DNA polymerase (e.g., Qiagen Beverly)

10uL of inorganic pyrophosphate (inorganic pyrophosphate), 6mM

0.04U apyrase

Water to 100uL

Wherein the 5x buffer comprises a mixture of:

50uL Tris acetate, 1M, pH 8.0

25uL of aqueous magnesium acetate, 1M

25uL of aqueous potassium acetate, 5M

50uL Triton X-100 surfactant (10%)

1mL of water

Pyrophosphorolysis of oligonucleotide 1 was then performed by incubating the mixture at 37 ℃ for 120 minutes, and the resulting reaction product was analyzed by gel electrophoresis.

The results of this analysis are shown in FIG. 1, where it can be seen that in the presence of oligonucleotide 2, oligonucleotide 1 is degraded to the length at which it is melted from oligonucleotide 2, leaving a shortened oligonucleotide of about 50 nucleotides in length. In contrast, in the presence of oligonucleotide 3, pyrophosphorolysis was not observed due to a single nucleotide mismatch at the 3' end of oligonucleotide 1. In the presence of oligonucleotides 4-6, oligonucleotide 1 pyrophosphorolysis proceeds to the single base mismatch position, in which pyrophosphorolysis stops, leaving the shortened oligonucleotide without further degradation.

Example 2: circularized and exonucleolytic digestion of unclirped DNA of degraded probes

Preparing single stranded first oligonucleotides 1(SEQ ID NO 7) and 2(SEQ ID NO 8) having the following nucleotide sequences:

wherein A, C, G and T represent nucleotides carrying the relevant characteristic nucleobases of the DNA and P represents the 5' phosphate group and wherein oligonucleotide 1 comprises a shortened oligonucleotide 2 obtained by pyrophosphorolysis of a suitable target oligonucleotide by oligonucleotide 2.

A third single stranded oligonucleotide 3(SEQ ID NO 9) was also prepared having the following nucleotide sequence:

wherein/3 ddC/represents a 3' dideoxycytosine nucleotide, and wherein oligonucleotide 3 has a 5' end complementary to the 3' end of oligonucleotide 1 and the internal region of oligonucleotide 2, and a 3' end complementary to the 5' ends of oligonucleotides 1 and 2.

A reaction mixture was then prepared having a composition corresponding to that obtained from the following formulation:

20uL 5 Xbuffer pH 8.0

10uL oligonucleotide 1 or 2, 3000nM

10uL oligonucleotide 3, 3000nM

7U Escherichia coli ligase

Water to 100uL

Wherein the 5x buffer comprises a mixture of:

50uL Tris acetate, 1M, pH 8.0

25uL of aqueous magnesium acetate, 1M

25uL of aqueous potassium acetate, 5M

50uL Triton X-100 surfactant (10%)

1mL of water

Oligonucleotide ligation was then performed by incubating the mixture for 30 minutes at 37 ℃.

A second reaction mixture is then prepared having a composition corresponding to that obtained from the following formulation:

20uL 5 Xbuffer pH 8.0

125U exonuclease III or equal volume water

Water to 100uL

Wherein the 5x buffer comprises a mixture of:

50uL Tris acetate, 1M, pH 8.0

25uL of aqueous magnesium acetate, 1M

25uL Potassium acetate, 5M aqueous solution

50uL Triton X-100 surfactant (10%)

1mL of water

The first and second reaction mixtures were then combined and the resulting mixture was incubated at 37 ℃ for 30 minutes to allow exonucleolytic digestion of any unclirped DNA. The resulting solution was then analyzed by gel electrophoresis.

The results of this analysis are shown in fig. 2, where it can be seen that the shortened oligonucleotide (oligonucleotide 1) is effectively circularized by the ligation reaction and left behind in the subsequent exonuclease digestion, while the non-shortened oligonucleotide (oligonucleotide 2) is not circularized and is effectively digested.

Example 3: amplification of circularized probes

A pair of single-stranded oligonucleotide primers 1(SEQ ID NO 10) and 2(SEQ ID NO 11) having the following nucleotide sequences were prepared:

wherein A, C, G and T represent nucleotides carrying the relevant characteristic nucleobases of DNA.

A reaction mixture was then prepared having a composition corresponding to that obtained from the following formulation:

20uL 5 × Phusion Flex HF reaction buffer

0.1uL of the final reaction mixture from example 2

Water to 100uL

A second reaction mixture was also prepared having a composition corresponding to that obtained from the following formulation:

20uL 5 × Phusion Flex HF reaction buffer

10uL betaine, 2.5M

10uL oligonucleotide 1, 3000nM

10uL oligonucleotide 2, 3000nM

10uL dNTP，2mM

2U Phusion Hot Start Flex DNA polymerase

Water to 100uL

The second reaction mixture was then combined with 0.1uL of the first reaction mixture and the resulting mixture was incubated at 98 ℃ for 1 minute followed by 30 cycles (98 ℃ C. times.20 seconds; 55 ℃ C. times. 30 seconds; 68 ℃ C. times.30 seconds) to allow exponential amplification by polymerase chain reaction.

The resulting reaction product was then analyzed by gel electrophoresis, the results of which are shown in fig. 3. From this analysis, it can be seen that when shortened oligonucleotides are present and circularized in example 2, a large amount of product is produced by this amplification. In contrast, when the non-shortened oligonucleotide is present and no circularization occurs in example 2, there is no observable amplification of DNA.

Example 4: pyrophosphorolysis using pyrophosphate analogues (pyrophosphates analoges)

Preparing a single stranded first oligonucleotide 1(SEQ ID NO 12) having the following nucleotide sequence:

wherein A, C, G and T represent nucleotides carrying the relevant characteristic nucleobases of the DNA; f represents a deoxythymidine nucleotide (T) labeled with an Atto 594 dye using conventional amine ligation chemistry, and Q represents a deoxythymidine nucleotide labeled with a BHQ-2 quencher.

Another single stranded oligonucleotide 2(SEQ ID NO 13) was also prepared having the following nucleotide sequence:

wherein X represents an inverted 3' dT nucleotide such that when oligonucleotide 2 anneals to oligonucleotide 1, the 3' end of oligonucleotide 1 is recessed to become a target for pyrophosphorolysis, while the 3' end of oligonucleotide 2 is protected from pyrophosphorolysis by the presence of the terminal inverted nucleotide.

A reaction mixture was then prepared having a composition corresponding to that obtained from the following formulation:

20uL 5 Xbuffer pH 8.0

10uL oligonucleotide 1, 1000nM

10uL oligonucleotide 2, 1000nM

2.5U Mako DNA polymerase (e.g., Qiagen Beverly)

10uL of inorganic pyrophosphate, 6mM of OR imino diphosphate and 10mM of OR water

Water to 100uL

Wherein the 5x buffer comprises a mixture of:

50uL Tris acetate, 1M, pH 8.0

25uL of aqueous magnesium acetate, 1M

25uL of aqueous potassium acetate, 5M

50uL Triton X-100 surfactant (10%)

1mL of water

Pyrophosphorolysis of oligonucleotide 1 was then performed by incubating the mixture at 37 ℃ for 75 minutes. As oligonucleotide 1 is gradually pyrophosphorolyzed, the fluorescent dye molecule separates from the quencher, and is then able to generate a fluorescent signal. The increase in this fluorescence during incubation is monitored with a Clariostar microplate reader (e.g., BMG Labtech) and used to infer the rate of pyrophosphorolysis of the oligonucleotide in the presence of inorganic pyrophosphate, iminodiphosphate, or water.

The results of this experiment are shown graphically in fig. 4. Accordingly, pyrophosphorolysis occurs in the presence of pyrophosphoric acid or iminodiphosphoric acid, but does not occur in the absence of pyrophosphoric acid or iminodiphosphoric acid. Similarly, in a comparative experiment in the absence of polymerase, no fluorescent signal was generated. Pyrophosphorolysis in the presence of pyrophosphate produces free nucleotide triphosphate, while pyrophosphorolysis in the presence of iminodiphosphate produces modified free nucleotide triphosphate (2 '-deoxynucleoside-5' - [ (β, γ) -imino ] triphosphate with O between β and γ phosphates replaced by an N — H group).

Example 5: melting curve analysis

The method of the invention was performed to detect the presence of three different mutations that may occur in the human EGFR gene and to identify said mutations: T790M (exon 20), C797S (exon 20) and L861Q (exon 21).

6 samples containing wild-type genomic DNA were prepared. Three of these samples were spiked with a single synthetic mutant sequence (spike) for each of the three mutations of interest, such that the final mutant allele fraction in these samples was 1%. To each sample was added a probe oligonucleotide A designed to detect a different single mutation₀：

The samples were pyrophosphorolyzed by addition of inorganic pyrophosphate ions (inorganic pyrophosphate ion) and Mako DNA polymerase and incubation at 41 ℃. After pyrophosphorolysis of the probe oligonucleotide, ligation was performed by adding E.coli ligase and a splint oligonucleotide having the following sequence:

following ligation, the samples were subjected to hyperbranched rolling circle amplification by adding dNTP, BstLF DNA polymerase, Sybr Green intercalating dye, mutation specific forward primer and universal reverse primer with the following sequences, followed by incubation at 60 ℃ for 70 min.

The temperature of the sample was then raised from 70 ℃ to 95 ℃ and fluorescence measurements were taken every 0.5 ℃. The resulting data curve was differentiated to generate melting peaks, the results of which are shown in FIG. 5. It can be seen that the presence of a distinct melting peak can therefore be used to infer the presence of a mutation targeted by a given probe, and the position of this peak can be used to identify the nature of the mutation.

Example 6: applications and uses

The applications described below provide some examples of how the method of the invention may be applied.

Companion diagnostics

The methods of the invention can be used to detect specific genetic markers in a sample, which can be used to help guide the selection of an appropriate therapy. These markers may be tumor specific mutations, or may be wild type genomic sequences, and may be detected using tissue, blood, or any other patient sample type.

Resistance monitoring

Repeated testing of patient samples during disease treatment may allow for early detection of resistance to treatment. One example of such an application is non-small cell lung cancer (NSCLC), where Epidermal Growth Factor Receptor (EGFR) inhibitors (e.g., gefitinib, erlotinib) are commonly used as first-line therapy. During treatment, tumors may often develop mutations in the EGFR gene (e.g., T790M, C797S) that confer resistance to drugs. Early detection of these mutations may allow patients to switch to alternative therapies (e.g., tagragisi).

Often, a patient being monitored for the development of resistance may be too ill to perform a repeat tissue biopsy. Repeated tissue biopsies can also be expensive, invasive, and carry associated risks. It is best to detect from blood, but very low copy numbers of the mutation of interest may be present in a reasonable blood sample. Monitoring therefore requires sensitive tests from blood samples using the method of the invention, wherein the method is simple and cost-effective to implement and can be performed periodically.

Relapse monitoring

In the present application example, patients declared disease free after treatment may be monitored over time to detect recurrence of the disease. This needs to be done non-invasively and requires sensitive detection of the target sequence from the blood sample. By using the method of the invention it provides a simple and low cost method which can be carried out periodically. The sequence targeted may be a universal mutation known to be common in the disease of interest, or may be a set of customized targets designed for a particular patient based on the detection of variants in the tumor tissue prior to remission.

Minimal Residual Disease (MRD) monitoring

For some cancers, residual cancer cells remain in the patient after treatment, which is a major cause of recurrence of cancer and leukemia. MRD monitoring and detection have several important roles: determining whether the treatment has eradicated the cancer or leaves a residue, comparing the efficacy of the different treatments, monitoring the remission status of the patient and detecting the recurrence of leukemia, and selecting the treatment that best meets these needs.

Screening

Population screening to detect disease early is a long-term goal, particularly in cancer diagnosis. The challenge is two-fold: identifying a set of markers that allows a reliable disease detection without too many false negatives, and developing a method with sufficient sensitivity and low enough cost. The methods of the invention can be used to process larger sets of mutations compared to PCR-based detection, but are simpler and less costly to work with than sequencing-based diagnostics.

Organ transplant rejection

When a transplanted organ is rejected by a recipient, DNA from the organ is shed into the recipient's bloodstream. This early detection of DNA will allow early detection of rejection. This can be achieved using a customized set of donor-specific markers, or by using a set of variants (some of which will be present in the donor and some in the recipient) known to be common in the population. Routine monitoring of organ recipients over time may be achieved through the low cost and simple workflow of the invention disclosed herein.

Noninvasive prenatal testing (NIPT)

It has long been known that fetal DNA is present in the blood of mothers, and the NIPT market has now been saturated with companies that use sequencing to identify mutations and count the copy number of specific chromosomes to enable detection of fetal abnormalities. The methods of the invention disclosed herein have the ability to detect mutations with very low allele fractions, potentially allowing for earlier detection of fetal DNA. Identifying common mutations in a given population would allow the development of assays that target mutations that may be present in maternal or fetal DNA, or allow the detection of abnormalities at earlier stages of pregnancy.

Example 7: single hole multiplexing

In some cases, there are multiple sets of mutations or target sequences whose presence should be identified rather than the identity of any one target. In other cases, information about the presence and identity of the mutation or sequence is required. In both cases, it is beneficial to multiplex the reactions so that more than one target can be assayed in a single reaction volume. This results in improved process efficiency, increasing the number of samples that can be processed at one time or the set size of the panel of targets that can be measured. When the presence of a target sequence is desired rather than its identity, multiplexing can be simplified to combining probes for more than one target into a single reaction volume. A key advantage of the method of the invention over standard PCR is that a single set of primers can be used to amplify all "activated" probes (A) in the final step of the reaction₂)。

Using the deletion of exon 19 on the EGFR gene, the inventors have shown that a 10-fold multiplexed detection was performed at 0.1% Mutant Allele Frequency (MAF) in a single reaction.

20 samples were prepared, each containing Wild Type (WT) DNA plus one of 10 different exon 19 deletions, labeled 0.1% or 0.5%. An added sample containing only WT DNA was used as a control. Probes for detecting all 10 different exon 19 mutations were added to each sample and the reaction was performed using standard conditions. The results (see fig. 6) show that at both 0.5% and 0.1% MAF, each mutation shows clear detection.

Detection can be carried out using standard techniques — intercalating dyes, labeled probes (Taqman, Scorpion, stem-loop primers), molecular beacons, or any other standard technique known to those skilled in the art.

When the identity of the target is required, it is most likely that a multi-color system will be used to identify which probe has been activated (A)₂). This naturally requires a probe design in which different "barcode" sequences are present in the probe for different targets, which are then used for identification. The identification can then be performed as described previously.

As with the 10-fold multiplex assay using 1 color, the inventors also demonstrated a single-well dual-color assay (the former using Taqman probes and the latter using stem-loop primers) in both linear and rolling circle amplification implementations of the methods of the invention. In this example, samples containing the T790M mutation or the C797S mutation at 0%, 0.1%, and 0.5% allele fractions were prepared. After pyrophosphorolysis and subsequent ligation, mutation targeting probe A labeled with a different fluorophore was used₀Specific primers or probes are used for carrying out rolling circle or linear PCR amplification on the sample. The results of rolling circle amplification using a labeled stem-loop primer are shown in fig. 7, where it can be seen that a signal was generated in the Cy5 detection channel in the presence of the T790M mutation, whereas in the sample containing the C797S mutation, a signal was observed in the TexasRed channel.

Example 8: background Signal calibration Using control probes

Three samples 1-3 were prepared, each sample containing 100nM final concentration of synthetic oligonucleotide 1(SEQ ID NO 24), which synthetic oligonucleotide 1 comprises the wild-type sequence of the L858R mutation region of exon 21 of the human EGFR gene:

a synthetic "mutant" oligonucleotide 2(SEQ ID NO 25) was prepared having the following sequence derived from the same region of the EGFR gene and further comprising the L858R mutation:

oligonucleotide 2 was added to samples 2 and 3 at final concentrations of 100pM and 1nM, respectively, such that 0.1% of the molecules in sample 2 contained the L858R mutation site and 1% of the molecules in sample 3 contained the mutation. Each sample was then divided into two reaction volumes. To the first reaction volume was added assay probe oligonucleotide 3(SEQ ID NO 26) at a final concentration of 10nM, which contained a perfect match 3' end to the mutated L858R sequence region, while to the second volume was added control probe oligonucleotide 4(SEQ ID NO 27) at the same concentration, which contained the same sequence, with the exception of the L858R mutation region, which contained a sequence that was mismatched to both the mutant and wild-type alleles:

oligonucleotide 3:

oligonucleotide 4:

the reaction volume was then pyrophosphorolyzed by adding 0.6mM pyrophosphate ions and 37.5U/mL Mako DNA polymerase and heating to 41 ℃ for 30 minutes. After this reaction, splint oligonucleotide 5(SEQ ID NO 28) was added to each reaction volume at a final concentration of 10nM, together with 50U/mL thermostable inorganic pyrophosphatase and 100U/mL E.coli ligase, and any pyrophosphorolyzed probe was circularized by incubation at 37 ℃ for 10 minutes. The E.coli ligase was then inactivated by heating to 95 ℃ for 10 minutes.

Oligonucleotide 5:

subsequently, the samples were subjected to exonuclease digestion by adding exonuclease III and T5 exonuclease and incubating at 30 ℃ for 5 minutes, followed by inactivating the exonuclease by heating to 95 ℃ for 5 minutes.

Two primer oligonucleotides 6(SEQ ID NO 29) and 7(SEQ ID NO 30), 0.4mM dNTP, 320U/mL BstLF DNA polymerase and 0.5 Xfinal concentration of Sybr Green intercalating dye were then added to each sample at a final concentration of 200 nM.

Oligonucleotide 6: 5'-TCGCAACATCCTATATCTGC-3'

Oligonucleotide 7: 5'-TGAGCTTTGACAATACTTGA-3'

The samples were incubated at 60 ℃ for 80 minutes and fluorescence from Sybr Green dye was measured in each sample once per minute. The results of the incubation are shown in figure 8(i) where it can be seen that in the presence of the assay probe the fluorescence signal is dependent on the presence of the L858R mutation, whereas the signal observed from the control probe is independent of the presence of the mutation and closely matches the signal observed from the probe in the absence of the mutation. FIG. 8(ii) shows the result of subtracting the control probe signal from the assay probe signal for each of the three samples. Quantitative detection of L858R mutations down to an allele fraction of 0.1% was therefore achieved by this technique without the use of a reference sample.

Various other aspects and embodiments of the invention will be apparent to those skilled in the art in view of this disclosure.

As used herein, "and/or" is considered to be a specific disclosure of each of the two specified features or components, with or without the other. For example, "a and/or B" is considered a specific disclosure of each of (i) a, (ii) B, and (iii) a and B, as if each were individually listed herein.

Unless the context indicates otherwise, the description and definition of features listed above is not limited to any particular aspect or embodiment of the invention, and applies equally to all aspects and embodiments described.

It will be further understood by those skilled in the art that while the present invention has been described by way of example with reference to several embodiments, the invention is not limited to the disclosed embodiments and that alternative embodiments may be constructed without departing from the scope of the invention as defined in the appended claims.

Sequence listing

<110> Biofidelity Co., Ltd

<120> improved method for detecting polynucleotide sequence

<130> P31404WO2

<150> EP18184575.1

<151> 2018-07-19

<150> PCT/EP2018/083227

<151> 2018-10-30

<160> 30

<170> PatentIn version 3.5

<210> 1

<211> 94

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 1 Single-stranded first oligonucleotide 1

<400> 1

cgctcgatgt atacgctcgg accactcgta cctcgaactg tcgttagtat ttttatatgt 60

agtttctgaa gtagatatgg cagcacataa tgac 94

<210> 2

<211> 70

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 1 Single-stranded oligonucleotide 2

<400> 2

agtacaaata tgtcattatg tgctgccata tctacttcag aaactacata taaaaatact 60

aactttaagg 70

<210> 3

<211> 70

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 1 Single-stranded oligonucleotide 3

<400> 3

agtacaaata tctcattatg tgctgccata tctacttcag aaactacata taaaaatact 60

aactttaagg 70

<210> 4

<211> 70

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 1 Single-stranded oligonucleotide 4

<400> 4

agtacaaata tgtcattatg agctgccata tctacttcag aaactacata taaaaatact 60

aactttaagg 70

<210> 5

<211> 70

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 1 Single-stranded oligonucleotide 5

<400> 5

agtacaaata tgtcattatg tgctgccata actacttcag aaactacata taaaaatact 60

aactttaagg 70

<210> 6

<211> 70

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 1 Single-stranded oligonucleotide 6

<400> 6

agtacaaata tgtcattatg tgctgccata tctacttcag taactacata taaaaatact 60

aactttaagg 70

<210> 7

<211> 94

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 2 Single-stranded oligonucleotide 1

<220>

<221> C at position 1 has a 5' phosphate group

<222> 1

<400> 7

cgctcgatgt atacgctcgg accactcgta cctcgaactg tcgttagtat ttttatatgt 60

agtttctgaa gtagatatgg cagcacataa tgac 94

<210> 8

<211> 132

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 2 Single-stranded oligonucleotide 2

<220>

<221> A at position 1 has a 5' phosphate group

<222> 1

<400> 8

atgttcgatg aggcacgata tagatgtacg ctttgacata cgctttgaca atacttgagc 60

agtcggcaga tataggatgt tgcaagctcc gtgagtccca caaaccaata acctcgtttt 120

ttatatgtag tt 132

<210> 9

<211> 57

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 2 Single-stranded oligonucleotide 3

<220>

<221> C at position 57 is 3' deoxycytidine

<222> 57

<400> 9

tatcgtgcct catcgaacat aactacatat aaaaaacgag gttattggtt tgtggcc 57

<210> 10

<211> 20

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 3 Single-stranded oligonucleotide primer 1

<400> 10

tgctcaagta ttgtcaaagc 20

<210> 11

<211> 20

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 3 Single-stranded oligonucleotide primer 2

<400> 11

cggcagatat aggatgttgc 20

<210> 12

<211> 39

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 4 Single-stranded oligonucleotide 1

<220>

<221> T at position 26 is deoxythymidine labeled with Atto 594 dye

<222> 26

<220>

<221> T at position 27 is deoxythymidine labeled with Atto 594 dye

<222> 27

<220>

<221> the T at position 30 is deoxythymidine labeled with BHQ-2 quencher

<222> 30

<400> 12

atgacctcgt aagccagtgt cagagtttttttc cagccgt 39

<210> 13

<211> 51

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 4 Single-stranded oligonucleotide 2

<220>

<221> T at position 51 is an inverted 3' dT

<222> 51

<400> 13

ttcacacggc tggaaaaaaa ctctgacact ggcttacgag gtcattagatt 51

<210> 14

<211> 78

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 5T 790M

<220>

<221> A at position 1 has a 5' phosphate group

<222> 1

<400> 14

atgttcgatg agctttgaca atacttgagc acggcagata taggatgttg cgaagggcat 60

gagctgcatg atgagctg 78

<210> 15

<211> 69

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 5C 797S

<220>

<221> A at position 1 has a 5' phosphate group

<222> 1

<400> 15

atgttcgatg agctttgaca atacttgaag ctcgcagata taggatgttg cgatagtcca 60

ggaggctgc 69

<210> 16

<211> 73

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 5L 861Q

<220>

<221> A at position 1 has a 5' phosphate group

<222> 1

<400> 16

atgttcgatg agctttgaca atacttgatc gatgcagata taggatgttg cgatccgcac 60

ccagctgttt ggc 73

<210> 17

<211> 36

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 5T 790M Splint oligonucleotide

<400> 17

tgtcaaagct catcgaacat gcccttcgca acatct 36

<210> 18

<211> 36

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 5C 797S splint oligonucleotide

<400> 18

tgtcaaagct catcgaacat tcctggacta tcgcat 36

<210> 19

<211> 34

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 5L 861Q splint oligonucleotide

<400> 19

agctcatcga acatctgggt gcggatcgca acaa 34

<210> 20

<211> 18

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 5T 790M primer

<400> 20

acatcctata tctgccgt 18

<210> 21

<211> 20

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> primer of example 5C 797S

<400> 21

catcgaacat tcctggacta 20

<210> 22

<211> 20

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 5L 861Q primer

<400> 22

tcatcgaaca tctgggtgcg 20

<210> 23

<211> 20

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 5 Universal reverse primer

<400> 23

atgttcgatg agctttgaca 20

<210> 24

<211> 80

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> oligonucleotide 1 synthesized in example 8

<400> 24

ccgcagcatg tcaagatcac agattttggg ctggccaaac tgctgggtgc ggaagagaaa 60

gaataccatg cagaaggagg 80

<210> 25

<211> 80

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 8 synthetic ` mutant ` oligonucleotide 2

<400> 25

ccgcagcatg tcaagatcac agattttggg cgggccaaac tgctgggtgc ggaagagaaa 60

gaataccatg cagaaggagg 80

<210> 26

<211> 71

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 8 measurement of Probe oligonucleotide 3

<220>

<221> A at position 1 has a 5' phosphate group

<222> 1

<400> 26

atgttcgatg agctttgaca atacttgatc gatgcagata taggatgttg cgacagtttg 60

gcccgcccaa a 71

<210> 27

<211> 71

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 8 measurement of Probe oligonucleotide 4

<220>

<221> A at position 1 has a 5' phosphate group

<222> 1

<400> 27

atgttcgatg agctttgaca atacttgatc gatgcagata taggatgttg cgacagtttg 60

gccggcccaa a 71

<210> 28

<211> 36

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 8 Splint oligonucleotide 5

<400> 28

tgtcaaagct catcgaacat gccaaactgt cgcaag 36

<210> 29

<211> 20

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 8 primer oligonucleotide 6

<400> 29

tcgcaacatc ctatatctgc 20

<210> 30

<211> 20

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> example 8 primer oligonucleotide 7

<400> 30

tgagctttga caatacttga 20